Edwards Lifesciences today announced the UK launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough RESILIA tissue technology, designed to extend the valve’s durability.* Edwards’ SAPIEN 3 Ultra RESILIA valve recently received CE Mark† for use in patients with heart disease due to native calcific aortic stenosis at all levels of surgical risk or due to the failure of either a transcatheter or a surgical bioprosthetic valve who are judged to be at high or greater risk for open surgical therapy. “Today’s patients are living longer, more active lives, with high expectations for their health and quality of life, so lifetime management of heart valve disease, and getting it right first … Continue reading Edwards launchs the sapien 3 ultra resilia valve in the UK with technology to enhance durability